Compounded Semaglutide vs Brand-Name Wegovy: What's the Difference?

Wegovy is the brand name for semaglutide, manufactured by Novo Nordisk, specifically FDA-approved for chronic weight management. It's a finished drug product that has undergone the full FDA approval process — clinical trials demonstrating safety and efficacy, manufacturing quality standards, standardized dosing, and post-market surveillance.

What you get with Wegovy: documented consistency of dose, manufacturing under FDA Good Manufacturing Practices (GMP), a clean and standardized formulation, and the legal backing of an approved drug product. The pre-filled auto-injector pen is also purpose-designed for patient use at home, with dose verification built in.

The cost reflects all of that — plus Novo Nordisk's R&D costs, marketing, distribution, and profit margin. Brand-name Wegovy at retail is approximately $1,349 to $1,600 per month without insurance or manufacturer discounts.

Compounded semaglutide is prepared by a licensed compounding pharmacy from semaglutide raw material (the active pharmaceutical ingredient, or API). The pharmacy combines the API with additional ingredients and produces a finished preparation — typically a multi-dose vial for subcutaneous injection with a separate syringe.

Compounded medications are not FDA-approved as finished products. They are legal under specific circumstances: Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act permit compounding when it serves a legitimate clinical purpose that the approved drug cannot fill. During the period when semaglutide was on the FDA drug shortage list (2022–2024), compounding was broadly legal because the shortage made the approved product unavailable to many patients.

The semaglutide shortage changed in 2024. The FDA removed semaglutide from its shortage list, which legally restricts compound pharmacies from continuing to produce copies of the commercially available drug. This has created a complicated and evolving regulatory situation. Some pharmacies have continued compounding, others have stopped, and enforcement has been inconsistent. Any provider recommending compounded semaglutide in 2026 should be able to explain the current regulatory status clearly.

Brand-name Wegovy has standardized, verified dosing. When the pen says 1.0 mg, independent testing has validated that it delivers 1.0 mg. Compounded semaglutide quality varies by the specific compounding pharmacy — the API purity, the concentration verification, the preparation method, and the sterility testing practices differ across pharmacies.

Reputable 503B outsourcing facilities (the higher-regulatory-tier compounding operations) have standards closer to pharmaceutical manufacturing — USP 797 sterility standards, independent third-party testing, and documented quality control. Lower-tier compounding pharmacies operate under less stringent oversight.

Some patients have reported unexpected side effects or variable results from compounded semaglutide, which has been linked in some cases to dose inconsistency. This is a real risk with any compounded medication from a pharmacy without rigorous quality verification.

The practical implication: if you pursue compounded semaglutide, the quality of the compounding pharmacy matters enormously. Not all pharmacies operate at the same standard, and knowing which your provider uses — and what quality verification they do — should be part of the conversation.

If a provider recommends compounded semaglutide, ask: which pharmacy do you use, what is their 503A or 503B designation, do they do independent third-party dose verification, and how do you currently interpret the FDA's regulatory position on compounding semaglutide post-shortage?

A provider who can't answer these questions clearly is not equipped to help you navigate this decision safely. A provider who can answer them and explains the tradeoffs transparently is the kind of physician oversight that makes a weight-loss program worth having.

At Summer House, we will not recommend any compounded medication without being able to explain the current regulatory status and the specific quality standards of the pharmacy we work with. Our approach is physician-led by design — clinical decisions are made with current information, not convenience.